Oct 21, 9:19 AM ET
Abbott plans to spin off its global Nutrition business, which has about $8.5 billion in annual sales, into a separate public company through a tax-free distribution to Abbott shareholders. Abbott expects the separation to be completed by the end of 2027, subject to conditions including regulatory approvals and final board approval, and says it will not affect Abbott's 2026 guidance.
- Nutrition business has approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites
- Abbott will keep sales of approximately $42 billion after the separation
- Separation expected to be completed by the end of 2027; Abbott expects one-time transaction charges, not yet quantified
- Daniel Salvadori will become chief executive officer of the new Nutrition company
Read the filing on SEC.gov ↗
Oct 21, 7:36 AM ET
Abbott reported third-quarter 2026 results on October 21, 2026, with net sales up 14.5% to $13.0 billion, aided by the Exact Sciences acquisition completed March 23, 2026. GAAP diluted EPS fell 43.6% to $0.53 after specified items, including about $670 million of legal settlements and $841 million of intangible amortization, while adjusted diluted EPS rose 9.2% to $1.42. The company tightened its full-year 2026 adjusted EPS guidance to $5.50 to $5.55, reaffirming the midpoint, which matters to shareholders because reported profit fell sharply even as sales and adjusted earnings grew.
- Third-quarter net sales were $13,013 million, up 14.5% reported and 7.0% on a comparable basis.
- GAAP diluted EPS was $0.53, down from $0.94 a year earlier; adjusted diluted EPS was $1.42, up from $1.30.
- Specified items included about $670 million in legal settlements and $841 million in intangible amortization.
- Full-year 2026 adjusted diluted EPS guidance was narrowed to $5.50 to $5.55, with the midpoint reaffirmed; projected comparable sales growth is approximately 6.0%.
Read the filing on SEC.gov ↗
Aug 20, 4:33 PM ET
Abbott agreed to resolve the Gill lawsuit and necrotizing enterocolitis claims for about 2,000 other infants for an aggregate of approximately $670 million, instead of continuing its appeal or paying about $600 million on the Gill judgment plus interest. The company states the agreements are a compromise and not an admission of liability, but the payment is a sizable cost, and roughly 1,700 lawsuits involving about 12,700 infants remain pending.
- Gill case: July 2024 Missouri jury verdict of $495 million, affirmed by the Missouri Court of Appeals in May 2026.
- Settlement: aggregate amount of approximately $670 million covering the Gill case and claims for about 2,000 additional infants.
- Alternative cited: paying approximately $600 million, the Gill judgment plus accrued interest to date.
- Remaining litigation: roughly 1,700 lawsuits involving claims for about 12,700 individual infants.
Read the filing on SEC.gov ↗
Jul 16, 7:36 AM ET
Abbott reported second-quarter 2026 net sales of $12.6 billion, up 13.0% from a year earlier, with comparable sales growth of 4.8%. It raised its full-year 2026 adjusted diluted EPS guidance to $5.45 to $5.60, but GAAP diluted EPS fell to $0.53 from $1.01 after large specified-item charges, including $658 million of intangible amortization.
- Q2 2026 net sales were $12.593 billion, up 13.0% reported and 4.8% comparable; Diagnostics rose 42.3% reported, boosted by the Exact Sciences acquisition completed March 23, 2026.
- Adjusted diluted EPS was $1.31, up from $1.26; GAAP diluted EPS was $0.53, down from $1.01, and GAAP net earnings were $928 million versus $1.779 billion.
- Full-year 2026 adjusted diluted EPS guidance was raised to $5.45 to $5.60 from $5.38 to $5.58; comparable sales growth guidance of 6.5% to 7.5% was reaffirmed.
- Abbott returned $2.1 billion to shareholders in the quarter via dividends and share repurchases, and declared a $0.63 quarterly dividend payable Aug. 17, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
